Thermoreversible hydrogels as a Drug Release Platform in Degenerative Disc Disease

Category
Bioactive Materials: Stem Cell and Regenerative Medicines
Year
2012
Authors
Marloes L.P. Langelaan, Renz van Ee, Klaas Timmer, Linda M. Kock, Audrey Petit, Hsiao-Yin Yang, Ruud Licht, Jacco Eversdijk, Keita Ito, Mike de Leeuw, Laura Creemers, and Nicole E. Papen-Botterhuis
Institutions
TNO, Eindhoven, The Netherlands; Department of Biomedical Engineering, Eindhoven University of Technology, The Netherlands; InGell Labs BV, Groningen, The Netherlands; UMCU, Utrecht, The Netherlands
Summary

For the treatment of degenerative disc disease (DDD) via injections in the nucleus pulposus, novel hydrogels were prepared with Layered Double Hydroxide (LDH) suspensions and pNIPAAM. These LDH suspensions were synthesized in a reproducible way and were degradable in PBS at 37°C. The hydrogels showed no shrinkage and measured complex moduli were around 1kPa at 37°C. Sterilization by gamma-radiation showed no negative effects on gel formation and very little cytotoxicity was found by in vitro cell tests. The hydrogels have successfully been loaded with the compound celecoxib and showed a release profile of this compound in time. Furthermore we investigated the effects of controlled release vs. a bolus injection of the drug in vitro in a 3D tissue engineered cartilage model system. Controlled release of celecoxib caused complete inhibition of PGE2 over the entire culture period (28 days), whereas the bolus injection inhibited PGE2 production up to 11 days.